Pages

Look Towards A New Future

Aug 10, 2010

Eisai Co. Ltd: PharmaVitae Profile now available at ReportsandReports

Dallas, TX: ReportsandReports announce it will carry Eisai Co. Ltd: PharmaVitae Profile Market Research Report in its Store.

Browse complete Eisai Co. Ltd: PharmaVitae Profile Report

Introduction

This analysis examines the historical and forecast performance for Eisai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Eisai’s performance against key rivals in the prescription pharmaceutical sector
  • See how the loss of patent protection on Eisai’s blockbuster products Aricept and AcipHex/Pariet will impact Rx revenue performance over 200713
  • Evaluate Eisai’s long-term growth potential following the acquisition of US companies Morphotek and MGI Pharma in 2007 and 2008 respectively

Table Of Contents

CHAPTER 1 ABOUT THIS PROFILE 2

Executive summary 2

Quarterly news update 2

Company introduction 2

Company sales 2

Company financials 2

Key products and competitors 3

Data sourcing 3

Sales data 3

Analyst consensus 3

CHAPTER 2 EXECUTIVE SUMMARY 4

Key findings 4

Prescription pharmaceutical sales performance, 2001-13 5

Financial performance, 2001-13 6

Eisai: PharmaVitae forecasts at a glance 7

Strategic insight 8

1) 2001-07: Impressive Rx revenue growth 8

2) 2007-10: M&A sustains Rx revenue 9

3) 2010-13: Life after Aricept and AcipHex? 10

Aricept and AcipHex/Pariet face generic competition over 2010-13 10

Launch portfolio unable to offset expiry declines 10

Further M&A on the horizon? 11

Operating margin remains robust despite revenue decline 11

SWOT analysis 12

Strengths 12

Weaknesses 13

Opportunities 13

Threats 15

CHAPTER 3 QUARTERLY NEWS UPDATE 20

Product developments 20

Deals and alliances 21

Product deals 21

Technology deals 22

M&A activity 23

Company announcements 23

Future product milestones 24

CHAPTER 4 COMPANY INTRODUCTION 25

Key findings 25

Background 26

Key corporate developments 26

M&A history 27

Merger of Sakuragaoka Research Laboratory and Nihon Eisai 27

Acquisition of Morphotek 27

Acquisition of Sanko Junyaku 27

Acquisition of MGI Pharma 28

Current corporate structure 29

Pharmaceuticals business unit structure 30

Pharmaceuticals business unit structure 30

Prescription pharmaceuticals (Rx) 30

Diagnostics 31

Consumer healthcare 31

CHAPTER 5 COMPANY SALES 32

Key findings 32

Prescription pharmaceutical sales and growth rate analysis, 2001-13 33

Product analysis 35

Product analysis, 2001-07 35

Product analysis, 2007-13 39

Therapy area analysis 43

Therapy area analysis, 2001-07 44

Therapy area analysis, 2007-13 46

Therapy area focus, 2001-13 48

Geographic analysis 49

Geographic analysis, 2001-07 50

Geographic analysis, 2007-13 51

Geographic focus, 2001-13 55

Launch/core/expiry analysis 56

Explanation of launch/core/expiry analysis 56

Launch analysis, 2007-13 57

Core analysis, 2007-13 59

Expiry analysis, 2007-13 60

Launch/core/expiry configuration, 2007-13 62

Molecule type analysis 63

Molecule type analysis, 2001-07 64

Molecule type analysis, 2007-13 65

Externalization analysis 67

Externalization analysis, 2001-07 68

Externalization analysis, 2007-13 70

CHAPTER 6 COMPANY FINANCIALS 73

Key findings 73

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 74

Financial statements, 2001-07 76

Profit and loss account, 2001-07 76

Balance sheet, 2001-07 78

Operating costs and profit analysis 80

Operating costs and profit analysis, 2001-07 81

Operating cost ratio and profit margin analysis, 2001-07 83

Operating cost ratio and profit margin analysis, 2007-13 84

Operating costs and profit analysis, 2007-13 86

Return on capital employed analysis 88

Capital employed analysis, 2001-07 89

Return on capital employed analysis, 2001-07 91

Market capitalization analysis 93

Market capitalization analysis, 2001-07 93

Total shareholder returns analysis, 2001-07 94

CHAPTER 7 KEY PRODUCTS AND COMPETITORS 95

Key findings 95

Overview 96

Central nervous system 97

Aricept 97

Overview 97

Sales forecast 98

Methycobal 100

Overview 100

Sales forecast 101

Lusedra 102

Overview 102

Sales forecast 103

Inovelon/Banzel 104

Overview 104

Sales forecast 105

Gastroenterology 107

AcipHex/Pariet 107

Overview 107

Sales forecast 108

Selbex 111

Overview 111

Sales forecast 112

Oncology 113

Aloxi 113

Overview 113

Sales forecast 114

Dacogen 116

Overview 116

Sales forecast 117

E7389 120

Overview 120

Sales forecast 121

Gliadel 123

Overview 123

Sales forecast 124

Infectious disease 125

E5564 125

Overview 125

Sales forecast 126

Immunology and inflammation 128

Humira 128

Overview 128

Sales forecast 129

CHAPTER 8 APPENDIX 130

R&D pipeline 130

Indication broadening pipeline 131

References 132

Abbreviations 133

Exchange rates 134

Browse complete Eisai Co. Ltd: PharmaVitae Profile Report

Browse all Healthcare Market Research Reports

Browse all Datamonitor Market Research Reports RSS

Browse all Latest Report

Related Reports:

Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile

Daiichi Sankyo Co., Ltd: PharmaVitae Profile

Bristol-Myers Squibb Co.: PharmaVitae Profile

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/